Overview of Dr. Nair
Dr. Suresh Nair is an oncologist in Allentown, PA and is affiliated with multiple hospitals in the area, including Lehigh Valley Hospital-Cedar Crest and Lehigh Valley Health Network - Muhlenberg. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 33 years. Dr. Nair accepts several types of health insurance, listed below. He is one of 18 doctors at Lehigh Valley Health Network - Muhlenberg and one of 43 doctors at Lehigh Valley Hospital-Cedar Crest who specialize in Oncology. He has more than 60 publications and over 500 citings.
Office
1240 S Cedar Crest Blvd
Suite 401
Allentown, PA 18103
Education & Training
- UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1987 - 1990
- Geisinger Health System (Danville)Residency, Internal Medicine, 1984 - 1987
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1984
Certifications & Licensure
- PA State Medical License 1985 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Start of enrollment: 2003 Jun 01
- Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2006 Mar 24
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 174 citationsHypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2Michael P. O'Connell, Katie Marchbank, Marie R. Webster, Alexander Valiga, Amanpreet Kaur
Cancer Discovery. 2013-10-08 - 24 citationsTherapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.Alexander N. Shoushtari, Walid K. Chatila, Arshi Arora, Francisco Sanchez-Vega, Havish S. Kantheti
Clinical Cancer Research. 2021-01-28 - 84 citationsOncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Farshad Nassiri, Vikas Patil, Leeor S Yefet, Olivia Singh, Jeff Liu
Nature Medicine. 2023-06-01
Press Mentions
- LVHN Participating in Potentially Groundbreaking Pancreatic Cancer Vaccine Trial. What You Need to KnowAugust 19th, 2024
- Navigating the Complexities of Oncology: Staying Current Amidst Rapid InnovationsAugust 16th, 2024
- LVHN, Local Patients Take Part in 'Revolutionary' Pancreatic Cancer Vaccine Clinical TrialAugust 11th, 2024
- Join now to see all
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Amerihealth HMO
AmeriHealth PPO
BCBS Blue Card PPO
Capital BC Keystone Health Plan Central HMO
Capital Blue Cross PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOGreat West PPO
HealthAmerica HealthAssurance PPO
Highmark BCBS ClassicBlue
Highmark BCBS PPOBlue
IBC Keystone HMO / POS
IBC Personal Choice PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: